4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes

AIM: Taxanes are anti-cancer agents used to treat several types of solid tumours. They are metabolized by cytochrome P450 (CYP) 3A, displaying a large pharmacokinetic (PK) variability. In this study, we evaluated the endogenous CYP3A4 marker 4β-hydroxycholesterol (4β-OHC) as a potential individual t...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Br J Clin Pharmacol
Päätekijät: de Graan, Anne-Joy M, Sparreboom, Alex, de Bruijn, Peter, de Jonge, Evert, van der Holt, Bronno, Wiemer, Erik A C, Verweij, Jaap, Mathijssen, Ron H J, van Schaik, Ron H N
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley & Sons, Ltd 2015
Aiheet:
Pharmacokinetics
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4574840/
https://ncbi.nlm.nih.gov/pubmed/26119961
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12707
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia